NEXI — Neximmune Share Price
0.000.00%
Last trade - 00:00- $0.00m
- -$2.42m
- 17
- 59
- 13
- 19
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0 | ||
| Price to Tang. Book | 0 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -1931.59% | ||
| Return on Equity | -230.06% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
NexImmune, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing an approach to immunotherapy designed to employ the body’s own T cells to generate an immune response that mimics natural biology. Its product candidates include NEXI-001 in acute myeloid leukemia (AML); NEXI-002 in multiple myeloma (MM), and NEXI-003, a solid tumor product candidate for Human papillomavirus (HPV) related cancers. The Company provides Artificial Immune Modulation (AIM), which is a nanoparticle technology platform. Its AIM technology enables it to construct nanoparticles that function as synthetic dendritic cells capable of directing a specific T cell-mediated immune response. The AIM nanoparticles employ signaling proteins to deliver instructions to T cells directing a desired immune response. The Company is also developing new AIM nanoparticle constructs and modalities for clinical evaluation in oncology and autoimmune disorders.
Directors
- Sol Barer NEC (73)
- Scott Carmer PRE (56)
- John Trainer CFO (47)
- Kristi Jones COO (58)
- Jerome Zeldis EVP (70)
- Jack Ragheb SVP
- Robert Knight OTH (70)
- Matt Schiller OTH
- Timothy Bertram IND (65)
- Paul D'Angio IND (62)
- Alan Roemer IND (42)
- Grant Verstandig IND (31)
- Zhengbin Yao IND (55)
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- June 7th, 2011
- Public Since
- February 12th, 2021
- No. of Shareholders
- 91
- No. of Employees
- 6
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 1,394,671
- Address
- 9119 Gaither Road, GAITHERSBURG, 20878
- Web
- https://www.neximmune.com/
- Phone
- +1 3018259810
- Auditors
- Ernst & Young LLP
Upcoming Events for NEXI
Neximmune Inc Annual Shareholders Meeting
Q1 2025 Neximmune Inc Earnings Release
Q2 2025 Neximmune Inc Earnings Release
Similar to NEXI
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
Adynxx
Pink Sheets on Nasdaq
FAQ
What is the Neximmune share price?
As of Today at 16:17 UTC, shares in Neximmune are trading at $0.00. This share price information is delayed by 15 minutes.
How has the Neximmune share price performed this year?
Shares in Neximmune last closed at $0.00 and the price had moved by -100% over the past 365 days. In terms of relative price strength the Neximmune share price has underperformed the S&P500 Index by -100% over the past year.
What are the analyst and broker recommendations for Neximmune?
The overall consensus recommendation for Neximmune is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Neximmune dividend yield?
Neximmune does not currently pay a dividend.
Does Neximmune pay a dividend?
Neximmune does not currently pay a dividend.
When does Neximmune next pay dividends?
Neximmune does not currently pay a dividend.
How do I buy Neximmune shares?
To buy shares in Neximmune you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Neximmune?
As of the previous close price of $0.00, shares in Neximmune had a market capitalisation of $0.00m.
Where are Neximmune shares listed?
Here are the trading details for Neximmune:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: NEXI
What kind of share is Neximmune?
Based on an overall assessment of its quality, value and momentum Neximmune is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Neximmune share price forecast for 2025?
The analyst consensus target price for shares in Neximmune is $2.00. That is 1999900% above the last closing price of $0.00.
Analysts covering Neximmune currently have a consensus Earnings Per Share (EPS) forecast of -$3.75 for the next financial year.
Find out moreWhat is the trend in the Neximmune share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Neximmune. Over the past six months, its share price has underperformed the S&P500 Index by -99.95%.
As of the last closing price of $0.00, shares in Neximmune were trading -99.99% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Neximmune PE Ratio?
The Neximmune PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Neximmune?
Neximmune's management team is headed by:
- Sol Barer - NEC
- Scott Carmer - PRE
- John Trainer - CFO
- Kristi Jones - COO
- Jerome Zeldis - EVP
- Jack Ragheb - SVP
- Robert Knight - OTH
- Matt Schiller - OTH
- Timothy Bertram - IND
- Paul D'Angio - IND
- Alan Roemer - IND
- Grant Verstandig - IND
- Zhengbin Yao - IND